GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Follow-Up Questions
GHRS 주식의 가격 성능은 어떻습니까?
GHRS의 현재 가격은 $14.01이며, 전 거래일에 increased 0.09% 하였습니다.
GH Research PLC의 주요 사업 주제나 업종은 무엇입니까?
GH Research PLC은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
GH Research PLC의 시가총액은 얼마입니까?
GH Research PLC의 현재 시가총액은 $869.2M입니다
GH Research PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 GH Research PLC에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 9명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
